நிறுவனம் இம்யூனோ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நிறுவனம் இம்யூனோ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நிறுவனம் இம்யூனோ Today - Breaking & Trending Today

Imfinzi combined with novel immunotherapies improved clinical outcomes for patients with unresectable

Imfinzi combined with novel immunotherapies improved clinical outcomes for patients with unresectable
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , United States , Daiichi Sankyo , Roys Herbst , Susan Galbraith , Company Immuno , Steering Committee , Lung Ambition Alliance , Company On Twitter Astrazeneca , Early Access Programme , Oncology At Yale Cancer Center , European Society For Medical Oncology , European Society , Medical Oncology , Yale Cancer Center , Smilow Cancer Hospital , New Haven , Executive Vice President , North America , Real World , Rare Diseases , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , தய்ச்சி சாங்கியோ , ராய்ஸ் மூலிகை , சூசன் கல்பிரைத் ,

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Update on KESTREL Phase III trial for Imfinzi

Update on KESTREL Phase III trial of Imfinzi with or without tremelimumab in the 1st-line treatment of recurrent or metastatic head and neck cancer

The KESTREL Phase III trial for AstraZeneca s Imfinzi (durvalumab) did not meet the primary endpoint of improving overall survival (OS) versus the EXTREME treatment regimen (chemotherapy plus cetuximab), a standard of care, in the 1st-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose tumours expressed high levels of PD-L1. Also, the combination of Imfinzi plus tremelimumab did not indicate an OS benefit in all-comer patients, a secondary endpoint.

Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: Metastatic head and neck cancer is a complex and challenging disease with a poor prognosis. While we are disappointed by these results, insights from the KESTREL Phase III trial will advance ou ....

United Kingdom , United States , Dave Fredrickson , Astrazeneca Imfinzi , Adrian Kemp , Company Immuno , Investor Relations Team , Company On Twitter , World Health Organization , Executive Vice President , Oncology Business Unit , South America , Innate Pharma , Tumour Drivers , Antibody Drug Conjugates , Cell Therapies , Accessed January , Clinical Medicine , Molecular Diagnostic Tests , Investegate Announcements , Investegate Company Announcements , Astrazeneca Plc , Regulatory News Service , Regulatory News Service And , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் ,